Carcinoma Hepatocellular clinical trials

Explore recruiting carcinoma hepatocellular clinical trials.

Recruiting carcinoma hepatocellular studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Carcinoma Hepatocellular trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS LIVER)

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

DUMELEP trial - Durvalumab (MEDI4736)/Tremelimumab in neoadjuvant and adjuvant setting in patients with HCC treated by percutaneous ablation procedure in curative intent

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Evaluation of Multiparametric dynamic whole-body 68Ga-PSMA PET imaging for Hepatocellular Carcinoma recurrence. HIMIKO study.

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab, versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE).

Belgium, Spain, Italy, France, Germany, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)

Germany, Belgium, Italy, France, Sweden, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Carcinoma Hepatocellular trials by city

Carcinoma Hepatocellular in Toronto Carcinoma Hepatocellular in Vancouver Carcinoma Hepatocellular in Montreal Carcinoma Hepatocellular in Calgary Carcinoma Hepatocellular in Edmonton Carcinoma Hepatocellular in Ottawa Carcinoma Hepatocellular in Winnipeg Carcinoma Hepatocellular in Quebec City Carcinoma Hepatocellular in Hamilton Carcinoma Hepatocellular in Kitchener Carcinoma Hepatocellular in London Carcinoma Hepatocellular in Halifax Carcinoma Hepatocellular in New York Carcinoma Hepatocellular in Los Angeles Carcinoma Hepatocellular in Chicago Carcinoma Hepatocellular in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease